6:01 PM
 | 
Aug 17, 2015
 |  BC Extra  |  Company News

Aveo gains on Novartis licensing deal

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rose $0.53 (45%) to $1.70 after it granted Novartis AG (NYSE:NVS; SIX: NOVN) an exclusive, worldwide license to preclinical candidate AV-380, in development to treat cachexia. Novartis paid $15 million...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >